Bharat Parenterals DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	FY23Mar 2023	FY22Mar 2022

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
	0.76×	0.75×
	2.07×	1.32×
	7.1%	10.1%
	0.83×	0.97×
	1.61×	1.31×
	14.9%	12.8%
	13.6%	12.8%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

BPLPHARMA₹1,912.60

Bharat Parenterals Limited

· Pharma & Health

₹ CrorePeersJENBURPH KPL MAKERSL NOVARTIND PARNAXLAB SGRL SHUKRAPHAR SUNLOCMcap ₹1,105 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY22 31/03/2022	FY23 31/03/2023
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.75	0.76
Interest Burden (Pretax/EBIT) ×	1.32	2.07
EBIT Margin %	10.13	7.12
Asset Turnover ×	0.97	0.83
Financial Leverage (Assets/Equity) ×	1.31	1.61
ROE (5-step product, year-end total equity) %	12.79	14.94
ROE (owners' profit / average owners' equity) %	12.82	13.63

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY23 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.